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Abstract 
The ProTide technology is a prodrug approach developed for the efficient intracellular 
delivery of nucleoside analogue monophosphates and monophosphonates. In this approach, 
the hydroxyls of the monophosphate or monophosphonate groups are masked by an 
aromatic group and an amino acid ester moiety, which are enzymatically cleaved-off inside 
cells to release the free nucleoside monophosphate and monophosphonate species. 
Structurally, this represents the current end-point of an extensive medicinal chemistry 
endeavour that spans almost three decades. It started from the masking of nucleoside 
monophosphate and monophosphonate groups by simple alkyl groups and evolved into the 
sophisticated ProTide system as known today. This technology has been extensively 
employed in drug discovery and it has already led to the discovery of two FDA-approved 
(antiviral) ProTides. In this work, we will review the development of the ProTide technology, 
its application in drug discovery and its role in the improvement of drug delivery and efficacy. 
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	1. Introduction 
Nucleoside analogues were first introduced a number of decades ago as an effective way of 
treating various diseases, such as cancer and viral infections like herpes simplex virus 
(HSV), human cytomegalovirus (HCMV), human immunodeficiency virus (HIV), hepatitis B 
virus (HBV) and recently also hepatitis C virus (HCV).1-6 Currently, there are more than 
twenty different nucleoside analogues available in the clinic to treat the viral infections and 
cancer.7, 8 These molecules enter the cell with the aid of transporters, such as concentrative 
nucleoside transporters as well as peptide transporters, or via passive diffusion.9, 10 Once 
inside the cell, the nucleoside analogues are activated by a number of nucleoside and 
nucleotide kinases which phosphorylate them in a stepwise manner resulting in the 
formation of the mono-, di- and tri-phosphorylated nucleoside analogue metabolites (Figure 
1).6, 11  
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Figure 1. Intracellular activation of therapeutic and experimental nucleoside analogues. NA: 
nucleoside analogue. 
 
The activated (phosphorylated) antiviral nucleoside analogues exert their therapeutic effects 
by targeting and inhibiting intracellular enzymes (usually the virus-encoded DNA or RNA 
polymerases) and/or by being incorporated into the viral nucleic acid chains leading to the 
termination of the elongation process.7, 8, 12 However, there are a number of limitations 
associated with the administration of nucleoside analogue drugs. Nucleoside analogues are 
structurally different to natural nucleosides making their phosphorylation by cellular or viral 
	kinases often inefficient.13, 14 This ultimately limits the formation of the active triphosphate 
metabolites, often the nucleoside analogue active metabolite.13 They also often demonstrate 
poor oral bioavailability due to their low intestinal permeability, as they are usually polar 
molecules that hinder their transport through the cell border via the paracellular route.15 
Additionally, the therapeutic use of many antiviral and anticancer nucleoside analogues is 
further limited by resistance, which occurs via a number of mechanisms8 that include 1) 
down regulation of the nucleoside kinases responsible for activating nucleoside analogues,16 
2) depletion of transporters that affect their efficient trafficking into the target cells,17-19 3) 
activation of phosphatases (i.e. 5’-nucleotidases) that dephosphorylate the active 
metabolites of nucleoside analogues,20, 21 and 4) increased catabolic bioconversion of the 
nucleoside analogues, e.g. (deoxy)cytidine deamination, which may yield inactive versions 
of some of the nucleoside analogues22, 23.  
To overcome these limitations, it was initially suggested that delivering phosphorylated 
metabolites of the nucleoside analogue would address some of these shortages. This notion 
was further supported by numerous studies that reported the poor phosphorylation of 
nucleoside analogues into their nucleoside monophosphates as the rate-limiting step in their 
in situ activation.24-27 However, the idea of using nucleoside analogue monophosphates as 
therapeutics faced two main challenges. First, these compounds would have poor in vivo 
stability due to de-phosphorylation in the blood stream, and second, their transport into cells 
will be inefficient because of the charged nature of the phosphorylated nucleoside. To 
address the P-O bond instability, Holý and De Clercq switched the P-O- bonds in the 
monophosphate group of nucleoside analogues into monophosphonate P-CH2- bonds.
28 
This led to improved in situ stability, which translated into longer half-lives of the nucleoside 
monophosphonates as compared to their monophosphates.28 This advance in the design of 
stable nucleotide therapeutics inspired the discovery of many nucleoside analogue 
monophosphonates some of which were eventually approved for clinical use as antivirals 
against HCMV [i.e. cidofovir], HBV [i.e. adefovir and tenofovir], and HIV [i.e. tenofovir] 
(Figure 2).7 
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Figure 2. Chemical structures of therapeutic nucleoside analogue monophosphonates, 
cidofovir, adefovir and tenofovir. 
 
Although the use of monophosphonates efficiently addressed the in situ and in vivo 
instability issue associated with monophosphate (P-O-) bonds, these compounds still had 
poor cellular uptake due to the negative charges on the monophosphonate group at 
physiological pH (< 7.4). This limitation acted as a challenge in the medicinal chemistry field 
to develop prodrugs of nucleoside analogue monophosphates and monophosphonates that 
can deliver them into cells more efficiently. Numerous prodrug technologies that mask either 
one or two of the oxygens of the monophosphate and monophosphonate groups making the 
molecule more lipophilic and hence improve transport into the cells have been developed.13, 
29-31 Among these prodrug approaches is the ProTide prodrug technology that was 
pioneered by Prof. Chris McGuigan (Cardiff, UK).32 This prodrug technology has proved to 
be a powerful tool in the discovery of efficacious nucleoside monophosphate and 
monophosphonate prodrug therapeutics.33 To date, it has delivered at least ten clinical 
candidates that reached, or successfully passed, phase I clinical trials.33 Although most of 
these nucleotide prodrugs were developed as antiviral agents against HIV, HBV, HCV and 
Ebola virus, the most recent ones are also being pursued as potential anticancer agents. 
Moreover, the ProTide prodrug technology has so far led to the discovery of two FDA-
approved (antiviral) drugs, tenofovir alafenamide (TAF)34 and sofosbuvir35 (Figure 3).13  
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Figure 3. Chemical structures of the two FDA-approved antiviral ProTides, tenofovir 
alafenamide (TAF) and sofosbuvir. 
 
Due to the effectiveness of the ProTide technology in the in vivo intracellular delivery of 
nucleoside analogue monophosphates and monophosphonates, there has been a growing 
interest in the application of this technology in drug discovery. The last comprehensive 
review on the development of the ProTide technology appeared in 2009 (Mehellou, Balzarini 
and McGuigan)32. However, at that time, the ProTides had just entered clinical trials and 
significant advances in their synthesis, metabolism and clinical studies have been achieved 
since then. Thus, we felt that there is a need for an updated and comprehensive report on 
the ProTide technology, which this review aims to address and therefore provide a much 
needed updated resource for the scientific community. 
2. Inception and evolution of the ProTides 
Initial work on the ProTides can be tracked to the late 1980s.36-38 The mission was to mask 
the oxygen atoms of phosphate groups in nucleoside monophosphate analogues so that 
they are neutral at physiological pH and hence have a better uptake into cells. The process 
started from the simple masking of the phosphate groups by alkyl groups but eventually 
evolved into the intelligent masking of the phosphate with aryl groups and amino acid esters, 
which can be cleaved-off inside the intact cells. Such development process, which took at 
least two decades, could be divided into six phases as discussed below. 
	Stage One: Alkyl and haloalkyl phosphate esters 
The first attempt of making nucleoside analogue monophosphate prodrugs was to mask the 
phosphate group of 9-β-D-arabinofuranosyladenine (AraA)39 monophosphate, which exerts 
antiviral activity, by simple dialkyl triesters (Stage 1, Table 1).36 Although these prodrugs led 
to increased stability towards adenosine/adenylate deaminases, they demonstrated a 
moderate biological activity.36 Similar results were found when the same principle was 
applied to the anti-cancer agent β-D-arabinofuranosylcytosine (AraC)40.37 However, when 
the dialkyl phosphate approach was used to mask the monophosphate group of the anti-HIV 
agent 3’-azidothymidine (AZT)41, no significant activity was observed in vitro.42 This was 
attributed to several parameters, but the most likely explanation for the lack of activity was 
due to the high stability of the dialkyl triesters, which hindered the eventual conversion to the 
biologically active 5’-O-triphosphate form of AZT.43 Masking the monophosphate groups of 
AZT and 2′,3′-dideoxycytidine (ddC)44 with haloalkyl derivatives also yielded agents with poor 
biological activity.45 In order to enhance the intracellular cleavage of the haloalkyl masking 
groups, more haloalkyl phosphate masking groups with halogen atoms incorporated either 
on one or in both masking groups were used for making AZT monophosphate prodrugs. 
However, these prodrugs also displayed moderate antiviral activities.46 However, the use of 
haloalkyl groups in AraA and AraC monophosphates displayed significant increases in 
biological activity (Stage 1, Table 1).47 This increase in activity was mainly attributed to 
increased lipophilicity, resulting in better membrane permeability of the prodrug.47 The lack 
of increased AZT activity through administration of haloalkyl prodrugs of AZT could now be 
explained by the fact that the first phosphorylation step of AZT is not the rate-limiting step in 
its activation pathway while it certainly is for AraA and AraC.48 Nevertheless, the alkyl and 
haloalkyl phosphate masking groups, especially for their application to AraA and AraC, 
indicated that these masking groups showed good activity due to better membrane-crossing 
ability, since the biological activity correlated with lipophilicicty, rather than increased 
intracellular levels of the phosphate species.36, 37, 47 Such conclusion shifted the thinking 
towards phosphate prodrugs to a different strategy. 
	Stage Two: Alkyloxy and haloalkyloxy phosphoramidates 
Subsequently, the design of nucleoside phosphate prodrugs focused on alkyloxy and 
haloalkyl phosphoramidate prodrugs (Stage 2, Table 1).  The move towards 
phosphoramidate prodrugs was provoked by the findings that the HIV protease can cleave 
an oligopeptide from the phosphate group of blocked nucleotide phosphoramidates.49 
Initially, a selection of AZT alkyloxy phosphoramidates with methyl-esterified amino acids 
were synthesised.42 These compounds showed better anti-HIV activity than the dialkyl AZT 
prodrugs.42 Although the anti-HIV activity did not correlate with the alkyl phosphate chain, it 
did correlate with the amino acid side chain with L-alanine showing the better activity.42, 50 
Retrospectively, this observation proved to be critical for the success of the ProTide 
technology in drug discovery since all of the ProTides that entered clinical trials and those 
that have been approved for clinical use bear an L-alanine moiety.33 Further studies into 
different, i.e. α, β and γ, types of amino acids, indicated the superiority of α-amino acids.51 
Encouraged by the influence of the amino acid moiety on the anti-HIV activity of AZT 
alkyloxy phosphoramidates, the masking of phosphate groups by the methyl-esterified 
amino acids and haloalkyl groups, which increased the membrane-crossing ability, were 
explored next. Haloalkyl phosphoramidates of AZT were synthesised with glycine, alanine 
and valine amino acids as well as ethyl, trifluoroethyl or trichloroethyl as the haloalkyl 
motifs.52 These, surprisingly, did not show good anti-HIV activity with the exception of the 
trichloroethyl alanine prodrug. Since no clear structure-activity relationship was apparent 
from the haloalkyl phosphoramidates, they were not pursued any further. However, the key 
finding of the enhancement of activity with nucleoside phosphoramidate prodrugs, especially 
with L-alanine, proved to be important for the future evolution of this nucleoside 
monophosphate prodrug strategy. 
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Ar = Ph or substituted Ph 
R = H, Me, -CH2iPr, -CH2Ph…etc. 
R1 = Me, Et, iPr, tBu, Bn…etc. 
Table 1. Stages of the development of the ProTide prodrug technology. 
Stage Three: Phosphorodiamidates 
Given that the introduction of amino acids to generate phosphoramidates led to enhanced 
anti-HIV activity, it was logical that the next step would be to mask both oxygen groups of 
the phosphate group by amino acid esters. Indeed, a series of amino acid methyl esters with 
different side-chains were used to mask both oxygens of the phosphate group of AZT 
monophosphate (Stage 3, Table 1).53 Unlike previous studies where L-alanine appeared to 
give the better biological activity, in these phosphorodiamidate systems amino acids with 
aromatic side-chains, e.g. phenylalanine, showed better improvement of biological activity.53 
Although this was surprising in the context of the ProTides’ development, such finding was 
consistent with other studies where a preference was found for amino acids with aromatic 
side-chains in the development of unrelated phosphoramidate diesters.29, 31 Although no 
	further studies with these phosphorodiamidates were conducted since the early nineties and 
the development of the ProTides moved on, phosphorodiamidates as phosphate prodrugs 
recently (in 2011) made a comeback.54 
Stage Four: Lactyl-derived systems 
Continuing with the probing of the phosphoramidates and particularly studies on the 
importance of the P-N bond, isosteric O-linked nucleoside analogues derived from lactic and 
glycolic acids of AZT were prepared and evaluated for their biological activity (Stage 4, 
Table 1).55 Although no significant improvement in the anti-HIV activity was noted for the 
actyl-derived AZT monophosphate prodrugs, the observed activity was found to correlate 
with the lengthening of the alkyl phosphate chain (R2) since longer chains resulted in poorer 
anti-HIV activity. As for the glycol systems (R1 = H), the prodrugs were generally more active 
than the lactyl systems. The poor anti-HIV activity of these phosphate prodrug systems was 
not very encouraging and they were therefore not optimised or explored any further.  
Stage Five: Diaryl phosphates 
The next masking groups studied in the design of a novel phosphate prodrug strategy were 
aryl motifs. Indeed, the masking of AZT monophosphate by diaryl motifs was pursued (Stage 
5, Table 1).56 These prodrugs showed good anti-HIV activity and, remarkably, some of them 
showed much better anti-HIV activity than the parent compound AZT.56 In the journey 
towards the ProTides, this was the first time a phosphate prodrug was more active than the 
parent compound. Interestingly, these phosphate prodrugs retained their anti-HIV activity in 
cell lines that were considered to be resistant to AZT.56 However, when these cells (T 
lymphocyte cell line, JM) were used for this study back in 1992, they were considered as 
AZT insensitive due to poor phosphorylation of AZT.57 But, it was later shown that such AZT 
resistance was a result of an active AZT-efflux pump rather than inefficient intracellular 
phosphorylation.58 Regardless of the exact AZT-insensitivity mechanism in this cell line, the 
AZT diaryl phosphate prodrugs were more active than their parent compound providing a 
clear indication of an increased delivery of AZT monophosphate into the cells. This notion 
was further supported by the fact that para-nitrophenyl phosphate masking groups had ca. 
	100-fold better anti-HIV activity than their unsubstituted phenyl masking groups most 
probably due to the electron-withdrawing effect of the para-nitro group that speeds-up the 
de-masking of the prodrugs in cells.56 A further study on the effect of the nature of the phenyl 
substituents on the antiviral activity of diaryl phosphate prodrugs of AZT was then 
conducted.59, 60 This study confirmed that stronger para-electron-withdrawing groups on the 
phenyl phosphate masking groups gave better anti-HIV activity.59, 60 Intriguingly, these AZT 
diaryl phosphate prodrugs as well as AZT did not exhibit any anti-HIV activity in a thymidine 
kinase (TK)-deficient human T-lymphocyte cell line (CEM/TK-).60 McGuigan and colleagues 
concluded that this might have been due to poor intracellular release of AZT 
monophosphate. The development of diaryl monophosphate prodrugs was not progressed 
any further and the focus turned back to phosphoramidates, which showed good biological 
activity.56 
Stage Six: Aryloxy phosphoramidates (generally referred to as ProTides) 
Inspired by the improvement of the biological activities of the earlier examples of nucleoside 
monophosphate prodrugs particularly the para-substituted aryls and the amino acid esters, 
McGuigan and co-workers took the next logical step, which was to combine these two 
masking groups in the design of new monophosphate prodrugs.61 Indeed, the masking of the 
AZT monophosphate group with para-substituted aryls and an amino acid ester was 
conducted and these efforts yielded prodrugs that showed improved anti-HIV activity as 
compared to the parent nucleoside AZT. In particular, the combination of a phenyl and L-
alanine methyl ester showed the most potent anti-HIV activity in this study, EC50 = 0.8 µM 
(AZT, IC50 (toxicity) ca. 100 µM).
61 Interesting structure-activity relationships on these 
aryloxy phosphoramidate prodrugs emerged from this study. Notably, there was a 
preference for the L-alanine amino acid as compared to L-leucine (> 10-fold) and glycine (> 
100-fold) while electron-withdrawing para-substituted aryls were less potent that their 
unsubstituted moieties.61 Further studies into these substitutions concluded that para-fluoro 
aryls did not largely affect the biological activity while para-nitro-substitutions had detrimental 
effects on the biological activity, namely a 100-fold loss in activity.62 In a separate study it 
	was shown that para-nitrophenyl-containing nucleoside monophosphate prodrugs were toxic 
even to uninfected cells.63 Remarkably, AZT aryloxy phosphoramidates retained their anti-
HIV activities in thymidine kinase deficient (TK-) cells.62 These observations provided a direct 
proof of the ability of aryloxy phosphoramidates to deliver intact nucleoside analogue 
monophosphates into intact cells. Hence, the masking of nucleoside analogue 
monophosphates and monophosphonates with an aryl motif and an amino acid ester, which 
is nowadays known as the ProTide technology, was extensively pursued in the future 
discovery of novel antiviral and anticancer nucleotide therapeutics. 
1. Synthesis of the ProTides 
Although the synthesis of the aryloxy triester phosphoramidate ProTides has recently been 
excellently reviewed by Pradere et. al,29 for the completion of this Review, we will briefly 
discuss the different strategies used in the synthesis of the ProTides. We will also include 
recent reports on the development and use of new catalysts that improve the synthesis of 
the ProTides, which have been published after the comprehensive review by Pradere et. 
al29. There are three different strategies for synthesising ProTides: 1) the coupling of a 
nucleoside with a diarylphosphite followed by subsequent oxidative amination 2), the 
coupling of the nucleoside with a phosphorochloridate reagent, and 3) coupling of an amino 
acid to a nucleoside aryl phosphate (Figure 4). 
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Figure 4. A representation of the three main strategies for synthesising ProTides. LG: 
leaving group. NA: nucleoside analogue. R: any ester. X: any aromatic substitution. 
 
Among these three strategies, the second synthetic strategy, which involves the coupling of 
the nucleoside to a phosphorochloridate is the most common method and has been the 
method of choice of the initial synthesis of the ProTides. The coupling reaction takes place in 
the presence of either the Grignard reagent tert-butyl magnesium chloride (tBuMgCl) or N-
methylimidazole (NMI), which act as a base. The choice of the base is often influenced by 
the nucleoside substrate, most precisely the number of hydroxyl groups that could couple to 
the phosphorochloridate. For instance, in ribonucleosides, the base used is often NMI and 
this generates mostly the 5’-O- phosphoramidates due to steric hindrance and the fact that it 
is a weaker base than tBuMgCl. However, in cases where the nucleoside has only one 
hydroxyl group, the base of choice is tBuMgCl, which often gives higher yields of the product 
as compared to NMI. Notably, the approach of coupling the nucleoside to a 
phosphorochloridate yields a mixture of diastereoisomers. In some cases, the two ProTide 
diastereoisomers exhibit similar potency and their development therefore is pursued as a 
mixture of diastereoisomers (see examples in Figure 10).64 In other cases, the two 
	diastereoisomers may have different rates of metabolism and hence varying potency. For 
instance, the Sp-diastereoisomer of the clinically used ProTide sofosbuvir exhibits a 10-fold 
increase in antiviral activity than its Rp-diastereoisomer.35 In these instances, the separation 
of the two diastereoisomers becomes necessary. The separation of these by column 
chromatography has proved to be a stern challenge.  
To address this, Ross et al65 developed a system that allows for the facile generation and 
crystallisation of single isomer phosphoramidating reagents that could be coupled to 
nucleosides to yield pure single ProTide isomers. From this study, phosphorochloridates 
with a pentafluorophenol were found to be optimal since the desired Sp-isomer 
phosphorochloridate was readily crystallised, stable and allowed for the formation of the Sp-
isomer ProTides, which is often the more active isomer.65  
Continuing on the theme of synthetic procedures with stereocontrol of the phosphorous 
chirality of the ProTides, researchers from Merck recently reported the discovery of a small 
molecule catalyst that, upon the addition to the reaction of a nucleoside with a 
phosphorochloridate, leads to the generation of a single isomer with significant preference 
for the 5’-hydroxyl compared to the 3’-one.66 However, the reported catalyst generates the 
Rp-isomer and not the Sp-one, which often shows better pharmacological activity. This 
represents a challenge for the wide use of this catalyst. Impressively, more work from Merck 
researchers led to the identification of various Lewis acids as being able to improve the 
yield, stereoselectivity and regioselectivity of the reaction of phosphorochlorides with 
nucleosides to generate ProTides.67 Indeed, a selection of Lewis acids were studied and 
dimethyl aluminium chloride emerged as the optimal catalyst for this reaction. 
In the synthesis of nucleoside monophosphonate ProTides three different synthetic 
strategies are employed (Figure 5). The first strategy involves the bis-chlorination of a 
phosphate group to form a monophosphonate dichloridate. This is then followed by the 
addition of 1:1 molar equivalents of the phenol and amino acid ester yielding the desired 
ProTides. Alternatively, in the second synthetic strategy, the monophosphonate group is 
	initially coupled to one phenol group using N,N'-dicyclohexylcarbodiimide (DCC) and the 
product is then chlorinated. Finally the chloride group is substituted by the amino acid ester.  
1. Saponiication
2. AA coupling
1. Bis-chlorination
2. a) (substituted) Phenol
    b) AA substitution
1. Phenol coupling
2. Chlorination
3. AA coupling
ProTide  
Figure 5. Synthetic strategies for accessing monophosphonate ProTides. AA: amino acid. 
NA: nucleoside analogue. R: any ester. X: any aromatic substitution. Y: O or CH2. 
 
For the third synthetic strategy, the starting material employed is the diphenyl-masked 
nucleoside monophosphonate, which first undergoes selective saponification that results in 
the removal of one of the phenyl masking groups. The product is subsequently coupled to 
the amino acid ester to generate the desired nucleoside analogue monophosphonate 
ProTide. Further details on the synthesis of the ProTides can be found in Pradere et. al29 
and Serpi et al68. 
2. Metabolism of the ProTides 
Once inside the cell, the ProTides require metabolism to release the nucleoside 
monophosphate. The metabolic conversion of the 2′,3′-didehydro-2′,3′-dideoxythymidine 
(d4T)69-71 monophosphate (d4T-MP) ProTide to the eventual active metabolite d4T-TP has 
been extensively studied in several cell systems, including human lymphocytes (Figure 6). 
	Beside efficient formation of d4T-MP, d4T-diphosphate (d4T-DP) and d4T-triphosphate 
(d4T-TP), an additional metabolite markedly accumulated upon exposure of the cell culture 
to the d4T-MP ProTide, which was identified as being the alaninyl d4T-MP. This metabolite 
may act as an intracellular depot form of d4T-MP, explaining not only the superior antiviral 
activity of the ProTide versus the parental d4T, but also the marked retainment of antiviral 
activity in thymidine kinase-deficient cells in which the parental d4T markedly loses antiviral 
efficacy.72, 73 Also, the activation pathway of the ProTides of d4T-MP and AZT-MP containing 
different amino acids and/or ester moieties has been investigated. It was found that overall, 
there was a close correlation between the anti-HIV activity of these prodrugs and their 
conversion rate to the amino acyl nucleotide metabolite (metabolite C, Figure 6).74, 75 The 
metabolic conversion process is believed to be mediated by a two-step enzymatic process, 
which eventually releases the active monophosphate (or monophosphonate) form of the 
parent nucleoside as summarised in Figure 6. 
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Figure 6. Postulated mechanism of ProTide metabolism illustrated using the ProTide of the 
anti-HIV agent d4T as an example.  
 
The first step involves the cleavage of the amino acid ester by intracellular esterases. 
Researchers at Gilead Sciences identified cathepsin A as a major esterase that mediates 
the hydrolysis of ester motifs of ProTides.76 Such finding has made cathepsin A widely used 
in the field in probing the hydrolysis of ProTides in vitro.64, 77-79 Notably, a second enzyme 
that was able to hydrolyse the ester group of the two antiviral ProTides studied, TAF and 9-
(R)-4-(R)-[[[(S)-1-[(ethoxycarbonyl)ethyl]amino]phenoxy-phosphonyl]methoxy]-2-fluoro-1–
furanyladenine (GS-9131)80 (structure not disclosed), was also reported in this study but its 
identity was not determined.76 In 2011, however, this identity of this second enzyme was 
established and was shown to be carboxylesterase 1 (CES1).81 Although both cathepsin A 
and CES1 were found to be expressed in primary hepatocytes, CES1 expression was 
	undetectable in clone A replicon cells.81 This indicated that in primary human hepatocytes, 
both cathepsin A and CES1 are involved in the hydrolysing of the carboxyl ester motif of the 
ProTides, whereas in clone A cells, cathepsin A is the major enzyme that mediates such 
process. Beyond cathepsin A and CES1, a series of cysteine and (lysosomal) serine 
proteases have also been identified as being able to hydrolyse the carboxyl ester motif of 
the ProTides in quiescent cells and peripheral blood mononuclear cells (PBMC).82  
Earlier work by McGuigan and colleagues83 into the efficiency of the ester group hydrolysis 
in various ProTides indicated that this is dependent on the structure of the ester moiety. In 
particular, it was noted that ProTides with a tert-butyl ester group were slower hydrolysed 
than those bearing other esters, e.g. methyl, isopropyl and benzyl, which correlated with the 
biological activity.83 Although the lipophilicity of the ester motif seemed to give an increase in 
biological activity most likely due to increased cellular uptake, the rate of ester hydrolysis is 
another influencing factor in the ultimate biological activity of the ProTides.83 For instance, 
ProTides with naphthyl esters yield more active ProTides than their phenyl ester 
counterparts due to higher lipophilicity and faster hydrolysis (Figure 7). However, 
propylbenzene esters, which are more lipophilic, are not as active as phenyl esters probably 
due to poor in vivo hydrolysis.  
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Figure 7. Effect of the ester motif on the ProTides’ biological activity. The data presented 
regard d4T, ProTides and were obtained from McGuigan et al.83 
 
In addition to the ester group’s influence on the overall lipophilicity of the ProTides and its 
effect on the biological activity, the aryl motif has significant impact on the lipophilicity. In 
McGuigan’s work, the aryl group mostly used was the phenyl group though the naphthyl 
group has also been explored. The biological activity between these two aryl motifs often 
correlated with lipophilicity and hence the naphthyl-containing ProTides exhibit a better 
biological activity than their phenyl counterparts. Notably, substitutions on these aryl motifs 
exerts a significant impact on the biological activity (Figure 8). Electron-withdrawing 
substitutions were found to be associated with increased biological activity as compared to 
the electron-donating groups. The position on the aryl group that allows maximum electron-
withdrawing effects, i.e. ortho and para, had more pronounced effects than the meta 
position.  
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Figure 8. Effect of the aryl group substitutions on the ProTides’ biological activity. The data 
presented regard d4T, ProTides and were obtained from Siddiqui et al.84 
 
Beyond the nature of the ester group, it has been shown that the nature of the amino acid of 
the ProTides also affects the rate of cathepsin A-mediated hydrolysis of the ester group 
(Figure 9).76 Indeed, cathepsin A was unable to hydrolyse ProTides with branched amino 
acids such as valine and isoleucine. Subsequent studies showed that the nature of the 
amino acid side chain, primarily its size (bulkiness) and charge, has great influence on what 
enzyme hydrolyzes the ester motif.82 Indeed, an interesting structure-activity relationship 
emerged from the influence of the amino acid on the rate of the metabolism of ProTides. For 
instance, it was found that the ester motif of ProTides with alanine were efficiently processed 
by esterases (e.g. leukocyte elastase and proteinase 3) and serine proteases, but not 
cysteine, aspartic, or metalloproteases.82 Amino acids with bulkier side chains, e.g. 
phenylalanine and leucine, were more efficiently hydrolysed by chymotrypsin-related serine 
proteases  such as cathepsin  G  and  chymase.82 
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Figure 9. Effect of the amino acid on the ProTides’ biological activity. The data presented 
regard d4T, ProTides and were obtained from McGuigan et al.85 
 
After the ester motif at the amino acid moiety is cleaved-off, a free carboxylate, which under 
physiological pH carries a negative charge, is generated. Subsequently, a nucleophilic 
attack by the carboxylate functionality on the phosphate or phosphonate group causes the 
loss of the aryl-leaving group yielding a highly unstable five-membered anhydride ring. The 
speed of the nucleophilic attack from the carboxylate on the phosphate or phosphonate 
group varies depending on the nucleoside. For instance, AZT metabolite A formation (Figure 
6) was slower than that of d4T.75 Interestingly, the hydrolysis of ProTides with ß-alanine did 
not release the nucleoside monophosphate, since the hydrolysis did not proceed beyond the 
hydrolysis of the ester motif.75 Metabolite B formation is followed by a rapid nucleophilic 
attack by a water molecule on the phosphate (option 1, Figure 6) or carbon of the carbonyl 
group of the amino acid (option 2, Figure 6) to open-up the ring and to  generate the 
phosphoramidate metabolite (metabolite C, Figure 6). Although no compelling evidence 
exists to whether the water molecule attacks the phosphate or the carbon of the carbonyl 
	group of the amino acid, which both yield the same product, the cleavage of the P-N bond at 
this stage has never been observed.86 
The final step in the metabolism of the ProTides is the cleavage of the P-N bond by a 
second enzyme known as a phosphoramidase-type enzyme (histidine triad nucleotide 
binding protein 1,87 HINT1).81, 88, 89 This eventually leads to the release of the nucleoside 
monophosphate/phosphonate. Notably, the cleavage of the P-N bond can be resistant to 
HINT1 as is the case with TAF. It is hypothesised that the hydrolysis of the P-N bond in this 
case proceeds because of the chemical instability of the P-N bond in the acidic environment 
of endosomes/lysosomes.90 
3. ProTides in Drug Discovery 
Since the invention of the ProTide technology by the McGuigan laboratory in the early 
1990s, this modality has been widely employed in the synthesis of many nucleoside 
monophosphate or monophosphonate ProTides. Although initially the structure activity 
relationship (SAR) studies were performed on pyrimidine nucleosides such as AZT and d4T, 
a wide variety of other ProTide derivatives have also been synthesized and antivirally 
evaluated. Notably, application of the phosphoramidate ProTide technology on purine 
nucleoside analogues such as 2’,3’-dideoxyadenosine (ddA) and 2’,3’-didehydro-2’,3’-
dideoxyadenosine(D4A),91 carbocyclic adenosine derivatives,92 and carbovir/abacavir93, 94 
often led to markedly enhanced antiviral potencies of such ProTides. More recently, it was 
even shown that ProTides of the antiherpetic acyclovir resulted in both anti-herpetic and 
anti-HIV activity,95, 96 and thus, enabled broadening of the antiviral spectrum of such drug. In 
this respect, it should be mentioned that the ProTide technology not only enables significant 
optimization of existing antiviral drugs, but it also allows conversion of apparently looking 
inactive molecules to active antivirals by the improved uptake and direct delivery of their 
activated (monophosphate) species. A series of ProTides have reached clinical trials33 with 
two of them already approved for clinical use.13 To highlight the usefulness of this prodrug 
technology in drug discovery, key ProTides that are currently reported to be undergoing 
clinical trials and those that have received FDA-approval will be discussed.  
	5.1. ProTides as Clinical Candidates 
5.1.1. Benzyl ((((2R,3R,5R)-5-(4-amino-2-oxopyrimidin-1(2H)-yl)-4,4-difluoro-3-
hydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate (NUC-1031)  
NUC-1031 (1, Figure 10)64 is a phenyl L-alanine benzyl ester ProTide of the FDA-approved 
anticancer nucleoside analogue gemcitabine (Gemzar™)97 and developed for clinical use by 
NuCana Biomed Ltd. Gemcitabine emerged as an ideal candidate for the application of the 
ProTide technology because of the emerging resistance against this anticancer therapeutic 
agent. Gemcitabine resistance mechanisms include inadequate conversion of gemcitabine 
into its pharmacologically active di- and tri-phosphate forms due to downregulation of 
deoxycytidine kinase, deamination of gemcitabine to its much less active uridine derivative 
and mutations in the membrane transporter that mediates its active uptake into cells.98  
A series of gemcitabine ProTides were synthesised and probed for their cytostatic 
activities.64 The lead structure from these studies was 1 as it exhibited significant 
antiproliferative activity, superior in vivo stability and an excellent PK profile.64  
A notable result that emerged from the ProTide was that it was able to effectively overcome 
gemcitabine resistance. This was attributed to three main reasons: firstly, cytidine 
deaminase is an enzyme found in both serum and cells and is known to catabolize 
gemcitabine. In order for deamination to occur, unprotected hydroxyl groups on the 3’- and 
5’-position of the nucleoside analogue must be present.99 ProTide 1 demonstrated 
resistance to deamination because of the presence of the phosphoramidate moiety on the 
5’-O-position of the ribose moiety. A second advantage of being resistant to deaminase 
breakdown is an increased safety profile, as lesser toxic metabolite (2’,2’-
difluorodeoxyuridine) would be produced.64 Secondly, it was found that the cellular uptake of 
1 was not dependent upon nucleoside transporters and that the ProTide was lipophilic 
enough to enter the cells via passive diffusion. This was deduced following an experiment 
involving dipyridamole –a known inhibitor of the human equilibrative nucleoside transporter 1 
(hENT1)– to mimic the downregulation of nucleoside transport in cancer cells. Gemcitabine 
was incubated with pancreatic PANC1 cancer cells in the presence of dipyridamole, and it 
	was found that its cytotoxic activity was significantly reduced, with the cytostatic activity 
decreasing from 611 nM to > 2000 nM (CC50).  Contrastingly, even with blockage of hENT1, 
the activity of 1 remained fairly constant (CC50 = 162 µM), thus confirming that the cellular 
uptake of 1 is independent of nucleoside transporters.64 Thirdly, the structure of the ProTide 
is such that it is able to overcome the rate-limiting first phosphorylation-mediated by 
deoxycytidine kinase which is downregulated in certain cancers. This was confirmed by little 
change in the activity of 1 when incubated with RT112 cancer cells in the presence of 2’-
deoxycytidine being the competing natural substrate for gemcitabine activation to its 5’-
monophosphate by 2’-deoxycytidine kinase (EC50 = 0.7 μM in the presence of 2’-
deoxycytidine compared to 0.2 μM in the dCyd absence). Conversely, the activity of 
gemcitabine decreased when 2’-deoxcytidine was co-administered as the two compounds 
competed for the same active site on the deoxycytidine kinase.64 
In vivo animal studies of compound 1 were conducted, focusing in particular on gemcitabine 
(partially) resistant pancreatic cancers. The initial results obtained were very promising. In 
mouse models with human tumour xenografts, 1 reduced the tumour size faster than 
gemcitabine and significant reductions in tumour size were noticeable on day 7 post 
administration of the ProTide. The body weight of the animals was also recorded to assess 
their tolerance to the compound. Overall, ProTide 1 was associated with less than 4% 
reduction in body weight and it was found that over the course of the treatment, the mean 
body weight change was less pronounced in mice that were treated with 1 compared to 
those treated with gemcitabine. This indicated that the gemcitabine ProTide was better 
tolerated than the parent nucleoside analogue.64 The pharmacokinetics of the ProTide were 
also considerably better than those of gemcitabine: the half-life of 1 was 7.9 h compared to 
1.5 h for gemcitabine. The ProTide also led to intracellular concentrations of the active 
gemcitabine triphosphate metabolite that was 13 times higher than achieved by 
gemcitabine.100 
Phase I/II clinical trials were conducted involving 68 patients and showed that 1 was 
effective in a variety of different cancers but most notably in patients with ovarian, pancreatic 
	and biliary cancers. Phase III studies will be conducted focusing on these cancers in 
particular. The ProTide was found to be stable in vivo, exhibiting a plasma half-life of 8.3 h. 
Maximum intracellular concentrations of the active metabolite were quickly achieved, peaked 
at 475 µM and were maintained for 24 h. In several patients, the tumour had shrunk by more 
than 30%, whereas in 33 patients, the disease had stabilised.101  
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Figure 10. Chemical structures of key ProTides undergoing clinical trials. 
 
5.1.2. Benzyl ((((2R,3S,5R)-5-(4-amino-5-fluoro-2-oxopyrimidin-1(2H)-yl)-3-
hydroxytetrahydrofuran-2-yl)methoxy)(naphthalen-1-yloxy)phosphoryl)-L-alaninate (NUC-
3373)  
Another ProTide currently being developed for clinical use by NuCana Biomed Ltd is NUC-
3373 (2, Figure 10),79, 102 a phosphoramidate prodrug of 5-fluoro-2’-deoxyuridine (FdU).  FdU 
is a metabolite which gets formed in vivo from the pharmacologically active anti-cancer 
agent 5-fluorouracil (5-FU). Initially discovered by McGuigan and his colleagues in 2011 
after extensive SAR studies,79 ProTide 2 displayed promising preclinical results and initial 
	studies highlighted its superiority over its parent nucleoside, 5-FU. The path towards the final 
structure of 2 began with McGuigan and his co-workers by synthesising and comparing 39 
different ProTides, with variations in the aryl, ester and amino acid regions.79 There was little 
difference observed in the potency of the ProTides upon varying the amino acid ester region, 
and also upon changing the nature of the amino acid. L-alanine has long been the amino 
acid of choice when formulating ProTides, but there was little to discern between L-alanine 
and the other amino acids in these experiments. Generally, the ProTides yielding the 1-
napthyl group displayed more potency than phenyl-containing ProTides, thus leading to the 
deduction that the 1-napthyl, benzyl ester-containing ProTide was the most effective.79 In 
order to determine the cytotoxic activity of 2, in vitro studies were conducted involving 
human tumour cell lines (colorectal, lung, ovarian, acute lymphoblastic leukaemia and 
cervix). Attention to thymidine kinase and the nucleoside transporter hENT1 was also given 
to investigate the characteristics of cancer resistance.  Xenograft mouse models were also 
used to further analyse the anticancer activity of the ProTide.103  
It was found that compound 2 was, on the whole, significantly more cytotoxic than 5-FU, 
displaying IC50 values 2- to 333-times lower in the majority of the tumor cell lines tested. The 
ProTide also produced 363-times more of the active metabolite (FdU) than 5-FU, thus 
further displaying its superiority in efficacy.  Thymidine kinase inhibition only slightly affected 
ProTide 2 (~ 4-fold) compared to FdU, that showed reductions in cytotoxicity of up to 136-
fold, respectively, indicating the independence of the ProTide for the FdU-activating enzyme. 
Significant results were obtained with the colorectal tumour xenografts: ProTide 2 inhibited 
tumour growth by 47%, compared to 25% tumour growth inhibition demonstrated by 5-FU.103 
Compound 2 was found to overcome the main mechanisms of resistance that is associated 
with 5-FU and other drugs within this family, such as decreased levels of the necessary 
phosphorylating (activating) enzyme thymidine kinase, which is required to produce the 
active metabolite; an overexpression of thymidylate synthase (an enzyme responsible for 
DNA synthesis and a target for FdUMP (the active metabolite of 5-FU), altered levels of 
thymidine phosphorylase, and reduced entry into the cells via nucleoside transporters.79, 102 
	ProTide 2 overcomes these pathways to resistance by preventing degradation by 
phosphorolytic enzymes, bypassing the need to be activated by thymidine kinase and being 
able to diffuse into cells, independent of nucleoside transporters such as hENT1.104 Given 
the encouraging results obtained in the pre-clinical studies, ProTide 2 entered phase I 
clinical trials in the first quarter of 2016 in pursuance of determining the pharmacokinetic 
profile of the ProTide, the safety of the compound in human participants and clinical activity 
of 2 in tumour-bearing patients.103 The trial itself consists of two parts: the first part 
assessing the optimum dose that will maximise the risk/benefit reward to the participants 
when given a weekly dose of the ProTide, administered as a single intravenous infusion. 
The second part will assess the same as part one, except the dosing interval which will be 
increased to fortnightly (www.clinicaltrials.gov, trial identifier: NCT02723240). 
5.1.3. 2-Ethylbutyl ((S)-(((2R,3S,4R,5R)-5-(4-aminopyrrolo[2,1-f][1,2,4]triazin-7-yl)-5-cyano-
3,4-dihydroxytetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)-L-alaninate (GS-5734)  
In 2014, there was a mass outbreak of the Ebola virus, most prevalent in Western Africa, 
although there were a number of reported cases in the USA and the United Kingdom. In 
West-Africa alone, there were a total of 28,616 confirmed cases in Guinea, Liberia and 
Sierra Leone, leading to 11,310 deaths (WHO 2016). To this date there is no drug treatment 
available on the market to treat this disease. However, GS-5734 (3, Figure 10)105, developed 
by Gilead Sciences, has shown promising results as a potential treatment for the Ebola 
virus. Although most of the interest in this compound has been due to its activity against 
Ebola, recently, 3 was reported to be a broad-spectrum antiviral agent since it exhibited 
potent antiviral activity against a variety of viruses including filoviruses, coronaviruses, and 
paramyxoviruses.106 
Compound 3 is a ProTide of an adenosine analogue which, following intracellular delivery, 
gets metabolised into the pharmacologically active nucleoside triphosphate form, which then 
inhibits viral RNA dependent RNA polymerase.105  
The activity of 3 was initially tested using cell-based assays, followed by the administration 
of the ProTide to rhesus monkeys that were infected with the Ebola virus. Rodent studies 
	were deemed not suitable to determine the pharmacokinetics of 3 due to the high serum 
concentrations of esterases present in many rodent species, which would prematurely 
degrade the ProTide and impact on the findings. Thus, rhesus monkeys were chosen as 
they closely resemble humans and they do not express a high serum esterase 
concentration.105 10 µM of 3 was incubated in a 2 h-pulse or 72 h-continuous incubation of 
Ebola virus-infected human primary macrophages, endothelial cells and liver cells to deduce 
its activity. 10 µM of the nucleoside analogue was also incubated for 72 h in human 
monocyte-derived macrophages for comparison. ProTide 3 was found to be rapidly 
metabolised in the primary macrophages, with maximum intracellular concentrations of 
nucleoside triphosphate being achieved after 4 h post incubation, with a half-life of 16 h. It 
was found that 3 displayed an EC50 value against Ebola virus of 0.086 µM in the human 
primary macrophages, 0.14 µM in the endothelial cells and 0.07 µM in the Huh-7 liver cells. 
In comparison, the nucleoside analogue displayed an EC50 value of greater than 20 µM in 
both the human macrophages and endothelial cells, and 1.5 µM in the liver cells. The 
cytotoxic concentration (CC50) of the ProTide in all cell lines was above 20 µM.  The different 
cell lines were also infected with different variants of the Ebola virus (Makona and Kikwit 
variants) and other filoviruses. The cell-based assays gave strong indication that compound 
3 would be effective in treating the other viruses as well.105 
The pharmacokinetics of 3 were examined in rhesus monkeys. After being administered 
intravenously with 10 mg/kg of the ProTide, 3 displayed a very short plasma half-life of just 
0.39 h. There was rapid distribution into the peripheral compartments within 2 h post 
administration, and a half-life in the peripheral blood mononuclear cells of 14 h was 
observed. Levels required to achieve a 50% inhibition of the Ebola virus were maintained for 
24 h.105 Compiling the pharmacokinetics results and tissue distribution data led to the 
conclusion that once daily dosing would be effective to achieve a clinical effect. 
In order to assess the efficacy of the ProTide, a blinded placebo-controlled study was 
conducted involving 12 Ebola-infected rhesus monkeys (6 per treatment group) in two 
different modalities.105 The first part involved intramuscular administration of 3 either on day 
	0 (same day as being infected with Ebola), or day 2. Part two of the study administered a 
loading dose of 10 mg/kg followed by once daily doses of 3 mg/kg, commencing at various 
days after virus exposure or 10 mg/kg administered on day 3 post virus exposure. All of the 
monkeys given 3 survived until the end of the trial; 50% survival was noted with the treated 
group of animals given 3 mg/kg compared to no survival in the placebo group. It was noted 
that monkeys given the 10 mg/kg dose after day 3 had 100% survival along with reduced 
signs associated with the Ebola virus (thrombocytopenia, coagulopathy).105 
Given the promising results obtained in the rhesus monkey study, a phase II clinical trial is 
due to be conducted in Liberia. Sponsored by the National Institute of Allergy & Infectious 
Diseases, 60 to 120 men infected with Ebola virus will be recruited and will be given a five-
day course of 3, administered once daily, followed by monitoring over a six-month period to 
determine the clearance of virus from a persistent genital reservoir (www.clinicaltrials.gov, 
trial identifier: NCT02818582).  
5.2. ProTides as Drugs 
There have been two ProTide drugs approved by the FDA for clinical use. Sofosbuvir 
(Sovaldi™), Figure 3, was approved by the FDA in December 2013 for the treatment of 
HCV.107 Sofosbuvir is a phosphoramidate prodrug of 2’-deoxy-2’-fluoro-2’-C-methyluridine, 
the parent nucleoside. Having emerged as the superior ProTide out of 50 other ProTides 
developed,35 sofosbuvir was acquired by Gilead Sciences, where it adopted the identity 
sofosbuvir and underwent further extensive clinical evaluation. Sofosbuvir was found to act 
by inhibiting the HCV NS5B polymerase, an enzyme responsible for the replication of the 
viral genome. Inhibition of this enzyme would result in RNA chain termination and ultimately 
stop the replication of HCV.35 Following cellular uptake by hepatocytes, sofosbuvir 
undergoes sequential hydrolysis by cathepsin A and CES1 to form the active nucleoside 
monophosphate. Further hydrolysis by HINT1 and subsequent phosphorylations yielded the 
pharmacologically active triphosphate metabolite, that exerts its action on NS5B 
polymerase.108 Initial animal studies of sofosbuvir were encouraging. The ProTide was well 
absorbed following oral administration in portal vein cannulated dogs, bioavailability was 
	9.9%, which equated to a fraction absorbed of 36%.109 In human subjects, the absolute 
bioavailability was not determined, although over 80% of the administered dose was 
absorbed. The absorption was rapid, with maximum concentrations (Cmax) of sofosbuvir 
achieved 0.5-2 h post oral administration and Cmax of the inactive parent nucleoside 
metabolite was achieved 2-4 h post administration and a half-life of 0.48-0.75 h. Ex vivo 
studies of the distribution of the anti-HCV agent showed a plasma protein binding of around 
82% in healthy subjects and 85% in subjects with end stage renal disease.108  
Studies using the diastereomeric mixture of sofosbuvir in humans showed that it was rapidly 
absorbed and metabolised in the liver according to the typical in vivo degradation of the 
ProTides (see Figure 6). Briefly, the isopropyl ester motif was hydrolysed into the naked 
carboxylate group and then the P-N bond of the phosphoramidate group was cleaved-off to 
afford parent nucleoside monophosphate.110 Notably, the parent nucleoside, an inactive 
metabolite, was detectable in the plasma and remained detectable for at least 24 h following 
the 100 and 800 mg dosing of the diastereomeric mixture of sofosbuvir.110 Although 
sofosbuvir showed little indication of being excreted renally (3.5% recovered in urine; renal 
clearance = 0.238 L/min), the inactive parent nucleoside was the predominant compound 
present in the urine (77.7%), indicating excretion via the kidneys. This was further confirmed 
when studies were conducted observing the pharmacokinetics of sofosbuvir in patients with 
impaired renal function – the renal clearance of the parent nucleoside was around 2-fold 
higher than the glomerular filtration rate, signifying active renal excretion of the metabolites 
of sofosbuvir.109 Phase II studies of sofosbuvir in combination with pegylated interferon and 
ribavirin established the doses required to provide an optimal effect, whilst minimising any 
potential adverse effects.111 Initial studies postulated that 200 mg or 400 mg doses of 
sofosbuvir with pegylated interferon and ribavirin were most effective, as 100 mg dosing was 
found to be sub-optimal due to low viral load decline than observed with the 200 mg and 400 
mg doses. At these doses, the incidence of adverse effects was low, with the most frequent 
adverse effects being fatigue and nausea.111 Coupled with the short half-life of sofosbuvir, 
once daily dosing was recommended as there was little accumulation of the drug.109 
	The safety of sofosbuvir was later confirmed in phase II clinical trials. It was postulated that 
as sofosbuvir is not metabolised via the cytochrome P450-3A4 enzymes, drug-drug 
interactions would be minimal. However, because it seems to induce the P-glycoprotein 
efflux pump, caution was advised with co-administration of carbazepine and rifabutin as the 
concentrations of sofosbuvir can decrease significantly.112, 113   
Single-group, open label phase III study of treatment-naïve patients with HCV genotypes 1, 
4, 5 and 6 treated with sofosbuvir plus pegylated interferon and ribavirin for 12 weeks 
indicated high potency of sofosbuvir.107 Indeed, 80% of cirrhotic patients versus 92% of 
noncirrhotic patients achieved a viral load below the lower limit of quantifications 12 weeks 
after completion of HCV treatment (SVR12). This indicated the efficacy of sofosbuvir in 
treating different HCV genotypes confirming similar earlier preclinical observations.114 In a 
placebo-controlled phase III study comparing sofosbuvir and ribavirin for 12 weeks with 
matched interferon ineligible controls in genotype 2 and 3 patients, sustained viral response 
was achieved in 78% of treated patients with 93% response rate in genotype 2 patients and 
61% in genotype 3 patients.115 In a study involving patients who had previously been treated 
with interferon who were  treated with either sofosbuvir and ribavirin for 12 weeks followed 
by placebo for 4 weeks or sofosbuvir and ribavirin for 16 weeks, response rates showed a 
73% SVR12 in the 16-week arm compared to 50% of the 12-week arm.  Impressively, 94% 
of genotype 2 patients achieved SVR12 within 12 weeks of treatment with sofosbuvir and 
ribavirin, while 87% achieved it within 16 weeks. As for genotype 3 patients, 30% of patients 
achieved SVR12 within 12 weeks compared to 62% within 16 weeks. Notably, 46% of the 
patients treated with sofosbuvir and ribavirin for 12 weeks had viral relapse compared to 
27% of the 16-week treatment arm. In another study, the efficacy of extended treatment of 
24 weeks of sofosbuvir plus ribavirin in genotype 3 patients was evaluated.116 The results 
showed that 93% of the 73 patients with genotype 2 who took part achieved SVR12 within 
12 weeks of sofosbuvir and ribavirin treatment, whereas 85% of the 250 patients with 
genotype 3 treated for 24 weeks with sofosbuvir and ribavirin achieved SVR12. This was the 
first large scale study showing the efficacy of prolonged interferon-free treatments in 
	genotype 3 patients. Given the excellent safety profile and pan-genotypic efficacy of 
sofosbuvir, it has been licenced for clinical use in combination with pegylated interferon, 
ribavirin and the NS5A inhibitors ledipasvir and velpatasvir depending on the HCV genotype 
to be treated.117 Collectively, this has made sofosbuvir a cornerstone in HCV therapy.   
TAF, Figure 3, is the latest ProTide-based drug approved by the FDA for the treatment of 
HIV.118 Developed by Gilead Sciences Inc., TAF is a ProTide of the acyclic nucleoside 
phosphonate drug tenofovir. Another prodrug of tenofovir, tenofovir disoproxil fumarate 
(TDF), had long been an FDA-approved treatment for HIV, however, the ProTide TAF 
demonstrated increased anti-HIV activity, higher in vivo stability and was endowed with 
lesser side-effects than both tenofovir and TDF.118 TAF is specifically accumulating in 
lymphatic tissue, and in the liver, and thus, holds also great potential for the treatment of 
HBV infections. Markedly lower plasma levels but significantly higher intracellular tenofovir 
concentrations are observed with TAF as compared to TDF, explaining the lower incidence 
of tenofovir-associated side-effects with respect of bone mineral density losses and kidney 
nefrotoxicity.119 The drug itself becomes phosphorylated following cellular uptake into the 
pharmacologically active diphosphate form and is a potent inhibitor of reverse transcriptase. 
Inhibition of this enzyme results in DNA chain termination and viral replication ceases to 
progress.120  
Early studies of TAF were conducted in dogs in order to characterise its pharmacokinetic 
profile and understand its permeability and efficacy as a potential treatment for HIV. Initial in 
vitro studies using hepatic and intestinal S9 fractions from both humans and dogs yielded 
similar results, highlighting the suitability of using dogs for the pre-clinical studies. In vitro 
experiments showed TAF to have half-lives of 31 minutes in both dog intestinal and hepatic 
S9 fractions, a plasma half-life of 92 minutes and a half-life of 28.3 minutes in an MT-2 cell 
extract.80 5 mg/kg of TAF were administered to the dogs; plasma concentrations peaked at 
1.58 µM, achieved at 0.14 h post administration. The levels of TAF decreased rapidly 
(undetectable after 2 h post administration), which was accompanied by an increase in 
tenofovir levels. Rapid accumulation of the active metabolite tenofovir diphosphate in the 
	peripheral blood mononuclear cells followed, with peak concentrations of 18 µM achieved at 
1 h post administration. The bioavailability of TAF was found to be dependent on the 
administered dose, with bioavailabilities of 1.7% and 24.7% at 2 mg/kg and 20 mg/kg, 
respectively.121 However, other studies found that oral administration of 10 mg/kg of TAF 
yielded a bioavailability of 17% when compared to the intravenous dose,80 with the majority 
of the drug metabolised in the kidneys and excreted in the urine.122  
An earlier study conducted by Eisenberg et al. in 2001123 compared the activity of the 
ProTide with tenofovir and its prodrug TDF. Following incubation with peripheral blood 
mononuclear cells, it was found that the levels of tenofovir and its metabolites were 10-30 
times higher compared to TDF and tenofovir, respectively.123 The in vitro anti-HIV activity of 
TAF was determined to be 1000-fold and 10-fold greater than tenofovir and TDF.80  
Following successful in vitro assessments of TAF, the ProTide progressed into a number of 
phase I and II trials, where the in vivo pharmacokinetics/dynamics of the ProTide was 
evaluated and compared to its predecessors, along with establishing the optimum dose of 
TAF. An initial study was conducted by Markowitz et al.,124 where either 40 mg or 120 mg of 
TAF or 300 mg of TDF were administered once daily for 14 days and the activity of both 
prodrugs as monotherapy for the HIV-1 infection was compared. The study showed that both 
40 mg and 120 mg of TAF resulted in higher intracellular concentrations of tenofovir 
diphosphate in PBMC than tenofovir. TAF also produced a greater net change in HIV-1 RNA 
compared to TDF, thus illustrating its superiority over the existing prodrug in terms of 
potency.124 
Phase II/III studies of TAF focused on its efficacy in different patient groups including, but 
not limited to, adults and adolescents. As tenofovir is eliminated via the kidneys, it was 
imperative to understand how renal function would affect both the accumulation of tenofovir 
in the body and also its excretion. TDF has been associated with effects on the bone and 
renal toxicity, leading to decreased glomerular filtration rates, increases in serum creatinine 
and increased risk of adverse renal events. This toxicity was attributed to its effect in the 
proximal tubule, with efficient uptake from plasma but less efficient efflux into urine resulting 
	in accumulation of tenofovir in the body.125 Therefore, a Phase 3 double-blinded study was 
conducted in which TAF was administered to patients with impaired renal function. Patients 
were given either 10 mg of TAF or 300 mg of TDF, each co-formulated with elvitegravir, 
cobicistat and emtricitabine. The study found that participants on the TAF treatment regime 
displayed a smaller increase in creatinine, less proteinuria, and significant decreases in 
bone mineral density.126  
TAF was demonstrated to be superior not only in its antiviral activity but also in the fact that 
therapeutic effects could be achieved at much lower doses than TDF, thus reducing the 
incidence of adverse effects. This led to the FDA approval of the ProTide in the treatment of 
HIV-1 in a combination therapy with other anti-HIV agents.118 Moreover, in November 2016, 
the FDA granted approval for a once-daily treatment of 25 mg TAF in patients suffering of 
chronic HBV infection (Gilead Sciences 2016). This followed extensive studies which 
highlighted the ProTides superiority over current therapies used to treat not only HIV, but 
also chronic HBV infections.127 
6. Conclusions and Outlook 
The ProTide technology has facilitated the discovery and application of a variety of 
nucleoside monophosphate and monophosphonate analogues in the clinic. It took many 
years of trial and error, mainly by the McGuigan group, to optimise the masking groups of 
the phosphate to yield the successful ProTide technology as we know it today. Although this 
technology has largely been used in the discovery of nucleoside-based ProTides as antiviral 
and anti-cancer agents, recently it was applied in the early discovery of nucleoside-based 
ProTides for Parkinson’s disease.78 Additionally, the ProTide prodrug approach is receiving 
increasing attention as a prodrug strategy for the intracellular delivery on mono-
phosphorylated non-nucleoside compounds such as glucosamine,128, 129 Sphingosine 1-
phosphate (S1P),130 4-phospho-D-erythronohydroxamic acid131 and 5-phospho 
erythronohydroxamic acid132. Together, these examples show the broad usefulness of this 
prodrug technology and highlight its potential in the discovery of non-nucleoside 
monophosphate and monophosphonate prodrugs as potential therapeutics as well. 
	Regardless of the substrates to which the ProTide technology is applied to either 
nucleosides or non-nucleosides, it has already proven to be a powerful technology in drug 
discovery and efficient intracellular delivery of the (activated) parental drug. Given its 
expanding applications, there is a real possibility that this technology will deliver new 
(nucleoside and non-nucleoside) ProTides for the treatment of a variety of other diseases 
beyond microbial infections and cancer. 
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Dedication 
This review was written in memory of Prof. Christopher McGuigan (1958-2016), who 
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